Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Wellington Management
BioCentury | Apr 4, 2025
Finance
Isomorphic’s $600M funding among four megarounds: Finance Report
Other nine-digit financings go to Airna, Atsena, Neurona
BioCentury | Feb 28, 2025
Finance
Eikon draws $350M private round, holding off on public markets
Plus BridgeBio cancer subsidiary finds SPAC route to market, in an otherwise sleepy week for fundraising
BioCentury | Jan 31, 2025
Finance
Versant, Orbimed lead $65M launch of GIP-focused start-up Helicore
In BioCentury’s Venture Report: Oncomatryx, Quibin raise cash in Spain; Atalanta draws $97M; Forbion’s BioEconomy Fund
BioCentury | Jan 11, 2025
Finance
Metsera, Maze will play canary in the IPO coal mine
Pair of Arch, Ra portfolio companies file to list on NASDAQ
BioCentury | Dec 19, 2024
Finance
Siteone’s $100M to bring non-opioid pain therapy into the clinic
BioCentury’s Venture Report also features a new European VC fund and $60M for Akamis Bio
BioCentury | Dec 12, 2024
Deals
Nvelop, Chroma merger creates opportunity for targeted epigenome editors
Nvelop CEO Jeff Walsh will lead nChroma, which has $75M in new funding and a lead for HBV
BioCentury | Aug 13, 2024
Management Tracks
Lyell, Juno veteran Albertson becomes Caribou’s CMO
Plus: 10x names CCO, CFO and updates from Ovid, Cerevance, Fore, Atavistik, Velia, SpyBiotech, Telomir, Sernova and Holoclara
BioCentury | Aug 9, 2024
Finance
Venture Report: Pair of crossover rounds for precision oncology, peptide biotechs
Plus: Financings for newcos Nilo, Jade, Red Queen
BioCentury | Aug 2, 2024
Finance
Public Equity Report: Day One’s PIPE, Heartseed’s Tokyo listing
Few deals amid selloff, fears of volatility
BioCentury | Jul 18, 2024
Finance
Venture Report: Five biotechs raise nearly $800M in two-day flurry
Plus: New capital for CytoReason, Truvian and Renalys
Items per page:
1 - 10 of 168